secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acrivon Therapeutics, Inc. (ACRV)
CIK:        0001781174
Form:       8-K
Filed at:   2023-12-08T23:59:59+00:00
Accession:  0001193125-23-291705
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Acrivon expands Akoya companion diagnostic deal to $17.3M for ACR-368 OncoSignature test
--------------------------------------------------------------------------------

- Third Amendment with Akoya increases total milestone payments to $17.3M through FDA pre-market approval for multiple indications.
- $3.8M in milestones already achieved and paid to date; cash runway unchanged from Nov 2023 10-Q.
- Expanded scope of work covers development of ACR-368 companion diagnostic test across multiple indications.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781174/000119312523291705/0001193125-23-291705-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781174/000119312523291705/d608194d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-291705

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer